

FACTSHEET – November 25, 2024

Prime Treatments, Testing and Advancements Index

DESCRIPTION

Throughout history, infectious diseases of all types have plagued society. Some of these have become so infamous, that they were defining moments of an entire generation. Research indicates that antibiotic-resistant microbes jump across species more easily than expected. Unfortunately, the list of infectious diseases continues to grow, whether it's due to population changes, growth in international travel, demand on food supply, or the convergence of animal and human health.

The COVID-19 pandemic is further proof that country borders don't matter. What matters is a frontline of defense that includes a robust pipeline of research and development for therapies, vaccines and tests. The market size of this industry is already estimated to be in the tens of billions of dollars, and is the focus of both small cap and large cap companies with an aggregate capitalization in the hundreds of billions USD. The Prime Treatments, Testing and Advancements index measures the performance of companies on this frontline and serves as a barometer for the entire industry.

The Prime Treatments, Testing and Advancements Index was designed to measure the performance of companies that are engaged in the following areas: performing research, development, and commercialization of treatments or vaccines for infectious diseases, or ii) the research, development, manufacturing, or provision of biological tests for patients.

The index is calculated on a Price Return, Net Total Return, and Gross Total Return basis. The data included herein uses the Gross Total Return version of the index.

HISTORICAL PERFORMANCE



FACTSHEET – November 25, 2024

Prime Treatments, Testing and Advancements Index

CHARACTERISTICS


ISIN / WKN	DE000SL0A030 / SL0A03	Base Value / Base Date	100 Points / 12.12.2019
Bloomberg / Reuters	PGERM Index / .PGERM	Last Price	131.89
Index Calculator	Solactive AG	Dividends	Reinvested
Index Type	Total Return	Calculation	09:30 am to 04:50 pm (EST), every 15 seconds
Index Currency	USD	History	Available daily back to 12.12.2019
Index Members	49		

STATISTICS


USD	30D	90D	180D	360D	YTD	Since Inception
Performance	-2.53%	-0.59%	2.27%	8.69%	-1.41%	31.89%
Performance (p.a.)						5.74%
Volatility (p.a.)	31.61%	22.67%	23.71%	23.89%	23.76%	32.65%
High	139.63	139.63	139.63	139.63	139.63	303.24
Low	123.70	123.70	122.72	111.54	111.54	96.75
Sharpe Ratio*	-0.99	-0.31	0.00	0.18	-0.26	0.04
Max. Drawdown	-11.41%	-11.41%	-11.41%	-18.84%	-18.84%	-64.76%
VaR 95 \ 99				-35.6% \ -56.1%		-52.0% \ -76.1%
CVaR 95 \ 99				-49.3% \ -72.5%		-72.2% \ -100.7%

* Up to 31 December 2021, ex-post Sharpe ratios use as input for the risk free rate term the London Inter-Bank Offered rates in the respective currencies of the index and at a term equal to the observation period. From 3 January 2022 onwards, Sharpe ratios will be / are calculated using as reference risk free rate input the overnight replacement rate for these currencies, namely SONIA (for GBP), SOFR (for USD) and EURIBOR Overnight (for EUR).

Composition by Currencies



Composition by Countries



FACTSHEET – November 25, 2024

Prime Treatments, Testing and Advancements Index


COMPONENTS AS OF 25-Nov-2024

Company	Ticker	Country	Currency	Index Weight (%)
BIONTECH SE	BNTX UW Equity	DE	USD	8.03%
LABCORP HOLDINGS INC	LH UN Equity	US	USD	6.36%
QUEST DIAGNOSTICS INC	DGX UN Equity	US	USD	6.31%
ALNYLAM PHARMACEUTICALS INC	ALNY UW Equity	US	USD	5.98%
IMMUNITYBIO INC	IBRX UW Equity	US	USD	5.84%
ZAI LAB LTD	ZLAB UQ Equity	KY	USD	5.72%
DYNAVAX TECHNOLOGIES CORP	DVAX UW Equity	US	USD	4.35%
BIO-RAD LABORATORIES INC	BIO UN Equity	US	USD	4.03%
IMMUNOCORE HOLDINGS PLC	IMCR UW Equity	GB	USD	3.78%
QUIDELORTHO CORPORATION	QDEL UW Equity	US	USD	3.70%
BIOCRIST PHARMACEUTICALS INC	BCRX UW Equity	US	USD	3.57%
MODERNA INC	MRNA UW Equity	US	USD	3.56%
VAXCYTE INC	PCVX UW Equity	US	USD	3.27%
NOVAVAX INC	NVAX UW Equity	US	USD	3.12%
OPKO HEALTH INC	OPK UW Equity	US	USD	3.00%
VIR BIOTECHNOLOGY INC	VIR UW Equity	US	USD	2.70%
ADAPTIVE BIOTECHNOLOGIES CORP	ADPT UW Equity	US	USD	2.19%
ARBUTUS BIOPHARMA CORP	ABUS UW Equity	CA	USD	1.72%
CUREVAC BV	CVAC UQ Equity	NL	USD	1.65%
CORMEDIX INC	CRMD UQ Equity	US	USD	1.48%
FULGENT GENETICS INC	FLGT UQ Equity	US	USD	1.48%
SIGA TECHNOLOGIES INC	SIGA UQ Equity	US	USD	1.39%
EMERGENT BIOSOLUTIONS INC	EBS UN Equity	US	USD	1.38%
ARCTURUS THERAPEUTICS HOLDINGS INC	ARCT UQ Equity	US	USD	1.26%
GILEAD SCIENCES INC	GILD UW Equity	US	USD	0.96%
ABBOTT LABORATORIES	ABT UN Equity	US	USD	0.87%
JOHNSON & JOHNSON	JNJ UN Equity	US	USD	0.79%
ORASURE TECHNOLOGIES INC	OSUR UW Equity	US	USD	0.78%
ATEA PHARMACEUTICALS INC	AVIR UW Equity	US	USD	0.76%
ABBVIE INC	ABBV UN Equity	US	USD	0.76%
PFIZER INC	PFE UN Equity	US	USD	0.76%
TAKEDA PHARM-ADR	TAK UN Equity	JP	USD	0.75%
OCUGEN INC	OCGN UR Equity	US	USD	0.71%
MERCK & CO. INC.	MRK UN Equity	US	USD	0.71%
ELI LILLY & CO	LLY UN Equity	US	USD	0.69%
SANOFI-ADR	SNY UW Equity	FR	USD	0.69%
ASTRAZENECA PLC-SPONS ADR	AZN UW Equity	GB	USD	0.67%
GSK PLC-SPON ADR	GSK UN Equity	GB	USD	0.66%
XBIOTECH INC	XBIT UW Equity	CA	USD	0.56%
REGENERON PHARMACEUTICALS	REGN UW Equity	US	USD	0.54%
ENANTA PHARMACEUTICALS INC	ENTA UW Equity	US	USD	0.51%

FACTSHEET – November 25, 2024

Prime Treatments, Testing and Advancements Index

Company	Ticker	Country	Currency	Index Weight (%)
INFLARX NV	IFRX UW Equity	NL	USD	0.33%
INOVIO PHARMACEUTICALS INC	INO UR Equity	US	USD	0.28%
HILLEVAX INC	HLVX UW Equity	US	USD	0.26%
INVIVYD INC	IVVD UQ Equity	US	USD	0.21%
CHIMERIX INC	CMRX UQ Equity	US	USD	0.21%
RENOVARO BIOSCIENCES INC	RENB UR Equity	US	USD	0.20%
CEL-SCI CORP	CVM UA Equity	US	USD	0.10%





FACTSHEET – November 25, 2024

Prime Treatments, Testing and Advancements Index

For more information, please visit www.PrimeIndexes.com.

This index is owned by Level ETF Ventures LLC ("LEV"). All rights reserved. Prime Indexes and this index specifically are trademarks of LEV. Redistribution, reproduction and/or photocopying in whole or in part are prohibited without written permission. This document does not constitute an offer of services in jurisdictions where LEV or its respective affiliates do not have the necessary licenses. All information provided by LEV is impersonal and not tailored to the needs of any person, entity or group of persons. LEV receives compensation in connection with licensing its indexes to third parties. Past performance of an index is not a guarantee of future results.

LEV does not sponsor, endorse, sell, promote or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index. These materials have been prepared solely for informational purposes based upon information generally available to the public and from sources believed to be reliable.

THE CONTENT IS PROVIDED ON AN "AS IS" BASIS, LEV DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION.

Please visit www.PrimeIndexes.com for full disclaimers associated with the index and website.

